|
|
Major Milestones
Eisai in the United States |
| 1981 |
| Eisai U.S.A. established |
| |
| 1987 |
| Eisai Research Institute of Boston established |
| |
| 1992 |
| Eisai Corporation of North America established |
| |
| 1994 |
Process, research and bulk pharmaceutical company established in Andover, Massachusetts
Agreement forged with Pfizer Inc to co-promote Aricept® (donepezil hydrochloride) in the United States |
| |
| 1995 |
Prescription pharmaceutical sales company established as Eisai Inc.
American Depositary Receipt (ADR) established for trading in the over-the-counter market
New Drug Application (NDA) for Aricept® (donepezil hydrochloride tablets) filed with FDA |
| |
| 1996 |
Aricept® (donepezil hydrochloride tablets) 5-milligram and 10-milligram tablets receive FDA clearance for marketing
Medical sales force established |
| |
| 1997 |
Aricept® (donepezil hydrochloride tablets) launched
Research Triangle Park (RTP) pharmaceutical production and formulation R&D facility completed
Agreement forged with Janssen Pharmaceutica Inc. to co-promote Aciphex® (rabeprazole sodium) in the United States |
| |
| 1998 |
| NDA for Aciphex® (rabeprazole sodium) submitted to FDA |
| Production of Aricept® (donepezil hydrochloride tablets) begins at Research Triangle Park facility |
| |
| 1999 |
FDA clears Aciphex® (rabeprazole sodium) for marketing
Aciphex® (rabeprazole sodium) is launched |
| |
| 2001 |
Research Triangle Park facility expanded
Production of Aciphex® (rabeprazole sodium) begins at RTP |
| |
| 2002 |
Eisai Inc. reaches sales of $1 billion
Company acquires exclusive U.S. rights to promote Cerebyx® (fosphenytoin sodium injection) - Cerebyx® is a registered trademark of the Warner-Lambert Company
Eisai Medical Research Inc. is established to focus solely on clinical research and to expedite clinical drug development of new clinical entities and of new indications for marketed products |
| |
| 2003 |
Eisai Inc. Assumes U.S. Distribution Responsibilities for Aricept® (donepezil hydrochloride tablets)
Through a global agreement, Eisai Inc. and Teva Neuroscience Inc., the U.S. pharmaceutical operations of Eisai Co., Ltd. and Teva Pharmaceutical Industries Ltd., to copromote rasagiline, once approved by the U.S. Food and Drug Administration
Eisai Medical Research Inc. to codevelop rasagiline with Teva in the United States
Eisai Inc. expands its Research Triangle Park, North Carolina facility again to increase manufacturing and packaging capabilities; the facility more than doubles in size since its opening in 1997
Eisai Inc. assumes U.S. distribution responsibilities for Aciphex® (rabeprazole sodium) |
| |
| 2004 |
Through the Eisai Co., Ltd. global agreement, Eisai Inc. gains exclusive U.S. rights to manufacture and market rufinamide, once approved by the U.S. Food and Drug Administration; Eisai Medical Research Inc., the U.S. clinical research and development group will work with other Eisai research organizations globally to further develop rufinamide
Eisai Medical Research Inc. establishes new headquarters in Ridgefield Park, New Jersey.
Through the Eisai Co., Ltd. global agreement, Eisai Inc. acquires anti-epileptic drug Zonegran® (zonisamide) from Elan Corporation. By this agreement, Eisai obtains exclusive manufacturing, developing, and marketing rights for the drug in the U.S. |
| |
| 2005 |
Eisai Inc. reaches sales of $2 billion.
Eisai Inc. acquires exclusive U.S. rights to promote, further develop, and distribute Fragmin® (dalteparin sodium injection). |
| |
| 2006 |
Eisai Co., Ltd. and Eisai Inc. acquire exclusive rights for four oncology-related products from Ligand Pharmaceuticals.
Eisai Inc. breaks ground for a new pharmaceutical production and formulation research and development facility for parenteral oncology treatments at its RTP campus. |
| |
| 2007 |
Eisai Inc. moves to new headquarters in Woodcliff Lake, New Jersey.
Eisai Co., Ltd., Eisai Corporation of North America (ECA), and Morphotek® agree to acquisition of Morphotek, a biopharmaceutical company that discovers and develops monoclonal antibodies for oncology, inflammatory, and infectious diseases. |
|
Eisai Internationally |
| 1936 |
| Toyoji Naito establishes Sakuragaoka Research Laboratory, Eisai's predecessor |
| |
| 1941 |
| Nihon Eisai Co., Ltd. established |
| |
| 1942 |
| Sakuragaoka Research Laboratory merges with Nihon Eisai Co., Ltd. |
| |
| 1955 |
| Nihon Eisai Co., Ltd. changes its name to Eisai Co., Ltd. |
| |
| 1961 |
Company shares are listed on Tokyo Stock Exchange
|
| |
| 1966 |
Founder Toyoji Naito named chairman
Yuji Naito succeeds as president
Operations commence at Kawashima Plant in Japan |
| |
| 1970 |
| Manufacturing and sales company established in Indonesia |
| |
| 1974 |
| Manufacturing and sales company established in Malaysia and the Philippines |
| |
| 1979 |
| Sales support and management services company established in Singapore |
| |
| 1981 |
| Operations commence at Misato Plant in Japan |
| |
| 1982 |
| Tsukuba Research Laboratories completed |
| |
| 1987 |
| Pharmaceutical sales support company established in Taiwan |
| |
| 1989 |
Eisai Europe Ltd. established in the United Kingdom
Yuji Naito named Eisai's chairman, with Haruo Naito as new president
Pharmaceutical sales support company established in Thailand |
| |
| 1991 |
| Pharmaceutical sales support company established in Hong Kong |
| |
| 1992 |
Eisai London Research Laboratories, Ltd. established in the United Kingdom
Health Care Science Institute established |
| |
| 1994 |
Sales company established in United Kingdom
Eisai Co., Ltd. enters into global strategic alliance with Pfizer Inc. for Aricept® (donepezil hydrochloride tablets) |
| |
| 1996 |
Sales company established in Germany and France
Pharmaceutical manufacturing and sales company set up in China
|
| |
| 1997 |
Eisai Co., Ltd. enters into global strategic alliance with Janssen Pharmaceutica for Aciphex®/Pariet® (rabeprazole sodium)
Pariet® (rabeprazole sodium) proton pump inhibitor is launched in Japan
|
| |
| 1999 |
| Aricept® (donepezil hydrochloride tablets) launched in Japan |
| |
| 2001 |
| Sales company established in Spain |
| |
| 2003 |
| Eisai Co., Ltd. enters into strategic alliance with Teva Pharmaceutical Industries Ltd. for global codevelopment of rasagiline for Alzheimer's disease as well as U.S. copromotion for Parkinson's disease, once approved by the Food and Drug Administration |
| |
| 2004 |
Eisai Co., Ltd. signs in-licensing agreement with Novartis Pharma AG for the exclusive worldwide rights to manufacture, further develop, and market rufinamide for pharmaceutical use in the treatment of epilepsy
Eisai Co., Ltd. acquires anti-epileptic drug Zonegran® (zonisamide) from Elan Corporation. By this agreement, Eisai obtains exclusive manufacturing, developing, and marketing rights for the drug in the U.S., Europe, Canada, and Mexico. |
| |
| 2005 |
Eisai Co., Ltd. acquires exclusive worldwide rights outside of Japan to further develop, manufacture, and market ranirestat, once the product is approved by the FDA.
Eisai Co., Ltd. establishes pharmaceutical marketing subsidiaries in Italy and Switzerland. |
| |
| 2006 |
Eisai Co., Ltd. announces establishment of new pharmaceutical marketing subsidiaries in Portugal and Singapore.
U.S. FDA approves Aricept® for treatment of severe Alzheimer's Disease. |
| |
| 2007 |
| Eisai Co., Ltd. establishes new manufacturing subsidiary in the United Kingdom. |
|
| |
 Printer Friendly Version
|
|
Eisai Inc.'s pharmaceutical production and formulation research and development facility in Research Triangle Park, North Carolina
Mr. Toyoji Naito, founder of Eisai
Tsukuba Research Laboratories in Japan
Eisai London Research Laboratories, Ltd. in the United Kingdom
Eisai Inc.'s headquarters located in Woodcliff Lake, New Jersey
|
|
| |
|
|
|
|
|
|
|
|
